$40.65
-0.44-1.07%
Últ. Act.: Nov 12, 6:02 PM
Novo Nordisk AS fell 19.1% from $50.26 to $40.65, behind the S&P 500's +10.8%. Its worst day was Feb 23 (−16.4%), and its low came Mar 27 at $34.76.
Nov 12, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Novo Nordisk AS shares rose 7.3%, while the S&P 500 rose 0.5%.
+7.3% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
Novo Nordisk AS shares rose 9.1%, while the S&P 500 fell 0.1%.
+9.1% · S&P 500 −0.1%
Novo Nordisk AS closed at its highest level of the year, 27.3% above where the year started.
+2.8% · S&P 500 +0.5%
EPS of $1.00 beat the $0.89 estimate on $12.3B revenue (est. $12.1B); FY revenue guidance of $40.5B–$44.3B against the $47.3B consensus.
−6.2% · S&P 500 −0.5%
Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.REDEFINE 4 was an 84-week trial investigating CagriSema (a fixed dose
−16.4%, the year's worst day, on 99M shares, the year's heaviest volume · S&P 500 −1.0%
Novo Nordisk AS closed at its lowest level of the year, 30.8% below where the year started.
−4.5% · S&P 500 −1.7%
EPS of $1.04 beat the $0.87 estimate on $15.2B revenue (est. $11.1B); FY revenue guidance of $42.4B–$46.2B against the $45.4B consensus.
+2.0% · S&P 500 +1.4%
EPS of $0.96 beat the $0.81 estimate on $12.2B revenue (est. $11.3B).
+0.6% · S&P 500 −0.2%
Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo’s next innovation in
−8.0% · S&P 500 +1.6%
EPS of $0.89 beat the $0.81 estimate on $12.2B revenue (est. $11.4B).
+5.0% · S&P 500 +1.7%
Where it ended: a close of $40.65 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $0.68, revenue est. $12.1B).
Nothing in the past 12 months.
All NVO dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NVO and SPY from Benzinga historical bars. Not investment advice.